BRAF and colorectal carcinoma: Even with a prevalence of less than 20% in CRC, RNF43 has been described as one of the emerging predictive markers for treatment selection, especially in those with BRAF V600E mutations and MSI-H tumors with low MLH1 expression (Jiang et al., 2013; Giannakis et al., 2014; Tu et al., 2019; Yunos et al., 2020).